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Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden
The global rise of multi-drug resistant bacteria has resulted in the notion that an “antibiotic
apocalypse” is fast approaching. This has led to a number of well publicized calls for
global funding initiatives to develop new antibacterial agents. The long clinical history
of phage therapy in Eastern Europe, combined with more recent in vitro and in vivo
success, demonstrates the potential for whole phage or phage based antibacterial
agents. To date, no whole phage or phage derived products are approved for human
therapeutic use in the EU or USA. There are at least three reasons for this: (i) phages
possess different biological, physical, and pharmacological properties compared to
conventional antibiotics. Phages need to replicate in order to achieve a viable antibacterial
effect, resulting in complex pharmacodynamics/pharmacokinetics. (ii) The specificity of
individual phages requires multiple phages to treat single species infections, often as
part of complex cocktails. (iii) The current approval process for antibacterial agents has
evolved with the development of chemically based drugs at its core, and is not suitable
for phages. Due to similarities with conventional antibiotics, phage derived products such
as endolysins are suitable for approval under current processes as biological therapeutic
proteins. These criteria render the approval of phages for clinical use theoretically possible
but not economically viable. In this review, pitfalls of the current approval process will be
discussed for whole phage and phage derived products, in addition to the utilization of
alternative approval pathways including adaptive licensing and “Right to try” legislation.
Keywords: bacteriophage, phage therapy, adaptive pathways, alternative licensing, pharmaceutical regulation
INTRODUCTION
The discovery of penicillin in 1928 heralded a dynamic shift in modern medicine with antibiotics
quickly becoming one of the linchpins of modern medicine (Zaffiri et al., 2012). However,
in the 1960s, the “golden era” of the identification of novel antibiotics ended with modern
development focusing on the modification of existing drugs (Nathan and Cars, 2014) with only
four multinational pharma companies maintaining antibiotic divisions (Fair and Tor, 2014). This
lack of interest is not only due to the difficulties in discovering new antibiotic classes but also
decreasing financial returns within drug development (Scannell et al., 2012). It is particularly true
for anti-infective agents, where a median 10 day drug-treatment costs ∼US$ 85 for non-HIV
anti-microbial drugs compared to∼US$ 848 for anti-neoplastic drugs (Falagas et al., 2006). When
compared to the total number of drugs granted regulatory approval, anti-infective drugs represent
due to a poor return on overall investment which stifles their development (Figure 1; Piddock,
2012).
Cooper et al. Adaptive Licensing for Phage Therapy
FIGURE 1 | FDA Novel Drug Approval 2011–2015. Data obtained from (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.
htm). , Total; , anti-infective; , anti-bacterial.
Despite public concern about increasing levels of antibiotic
resistance, antibiotic consumption continues to increase,
particularly in the BRIC (Brazil, Russia, India, China) nations
(Van Boeckel et al., 2014). The ability to obtain antibiotics
without prescription, their subsequent misuse by patients (Li,
2014), and the continued use of antibiotics as a growth promoter
in agriculture (Cully, 2014), has contributed to an increase
in the number and scale of multi-drug resistant infections
(Molton et al., 2013). Increased consumption and fervid media
reporting has generated huge interest in the development of new
antibacterial agents and has led to the formation of a number of
working groups, such as the US Food and Drug Administration’s
(FDA) Antibacterial Drug Development Task Force
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Devel
opmentResources/ucm317207.htm; accessed 13th June 2016)
or the Biotechs from Europe innovating in Anti-Microbial
resistance (BEAM) Alliance (http://beam-alliance.eu/; accessed
13th June 2016). These groups have called for financial incentives
and patent extensions to be applied to antibacterial drug
development in order to stimulate research (Sonderholm, 2009;
Laxminarayan and Powers, 2011; Wise, 2015).
Interest in phage therapy (i.e., the clinical use of bacteriophage
based therapeutic products in humans), has been traditionally
confined to academic groups and a few clinical centers in
Eastern Europe, most notably the ELIAVA Institute in Tbilisi,
Republic of Georgia. However, the specificity of phages and the
enormous variation in human—bacteria—phage combinations
will lead to an immense number of obligatory clinical trials if
they are to be considered as a viable alternative to antibiotics.
This constitutes one of the primary obstacles for the industrial
development of phage based therapeutic products, in addition
to concerns over intellectual property protection. Nevertheless,
commercial interest has been piqued in the form of small
BioPharma companies (Table 1), but significant interest from
multinational pharmaceuticals is still lacking. These small
BioPharma companies have enabled a number of commercial
phage products to be approved for use in reducing food
contaminants (Endersen et al., 2014), but widespread use of
phage therapeutics in humans remains elusive in the West
(Kingwell, 2015).
The societal need for new antibacterial agents, and the
knowledge that phage therapy may work in practice, requires
the engagement of commercial entities to further develop phage
based products rather than proceeding as a purely academic
enterprise. However, what appears to limit the development
of phage products for human use is primarily associated with
development costs and regulations. Through the application
of new or refined regulations the development of phage
based pharmaceutical products may become faster and more
commercially attractive for companies.
In this article, the current requirements for the development
and approval of new antibacterial drugs are described with
emphasis placed on the challenges faced by phages and phage
based products. Potential alternative or additional approval
pathways within existing and proposed legislation and how phage
therapy could benefit from these pathways are also discussed.
THE REVIVAL OF PHAGE THERAPY
Since the early part of the 20th Century, bacteriophages have
been used to treat a range of different bacterial infections
(Kutter et al., 2010). However, since the introduction and success
of antibiotics in the mid-20th century, interest in phages as
antimicrobial agents within Western Europe and the US has
waned. Increasing problems with antibiotic resistant bacterial
infections has led to alternative strategies being sought. This has
in turn revitalized research into bacteriophages and their derived
products as antibacterial agents (Oliveira et al., 2015). Phage
therapy possesses advantages and disadvantages when compared
to conventional antibiotics. These advantages include the ability
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TABLE 1 | Summary of current phage based products in development for the treatment of human disease.
Company Product Type Target Application Company website
Micreos Staphefekt Endolysin S. aureus Topical https://www.staphefekt.com/en/newspublications
Intralytix ShigActive Phage Shigella Ingested http://www.intralytix.com/index.php?page=prod
AmpliPhi AmpliPhage-001 Phage Ps. aeruginosa –a http://www.ampliphibio.com/product-pipeline.html
AmpliPhage-002 S. aureus Topical
AmpliPhage-004 C. difficile –
Technophage TP-102 Phage –a Ulcers http://www.technophage.pt/index.php/r-d/product-
pipeline
TP-122 –a Respiratory
TP-132 –a –a
TP-107 –a Topical
Pherecydes
Pharma
PP021 Phage E. coli Burn and Skin http://www.pherecydes-pharma.com/pipeline.html
PP1131PP1231 Pseudomonas Burn, Skin, and Respiratory
tract infection
PP2351 Staphylococcus Bone, Joint, and Prosthesis
Avid
Biotics
Pyocin Phage
Derived
E. coli Diarrheal and food
poisoning
http://www.avidbiotics.com/programs/
Avidocin C. difficile –a
Pyocin Pseudomonas –a
Purocin Salmonella Food poisoning
Purocin Listeria Food poisoning
ContraFect CF-301 Phage
Derived
Lysins
S. aureus –a http://www.contrafect.com/pipeline/overview
CF-303 S.
pneumoniae
–a
CF-304 S. faecalis
and
E. faecium
–a
CF-305 S. agalactiae –a
CF-306 B. anthracis –a
CF-307 Group B
Streptococcus
–a
a Information not available.
of phages to self-replicate in the presence of a suitable bacterial
host. They act with minimal disruption to the local microbiota
and are relatively easy to isolate from environmental sources,
while the limited host range of lytic phages may detract from
their overall clinical usefulness. Although the advantages and
disadvantages of phage therapy have been briefly highlighted
here, they are discussed extensively elsewhere (Loc-Carrillo and
Abedon, 2011; Nilsson, 2014; Kutter et al., 2015).
Virulent phages have been isolated from a variety of
environments and proven in vitro to be efficient against a
large number of bacterial species (Mattila et al., 2015; Salem
et al., 2015; Sauder et al., 2016). In vivo testing has shown
that phages can be used to treat various types of infections
in animal models (Hawkins et al., 2010; Dufour et al., 2015;
Ghorbani-Nezami et al., 2015; Holguín et al., 2015; Galtier
et al., 2016) and also in humans (Kutter et al., 2010; Abedon
et al., 2011; Chanishvili, 2012; Rose et al., 2014; Abedon, 2015).
Results from these more recent in vitro and in vivo trials
have led to a deeper understanding of the unique nature of
phage therapy but have also highlighted the need for further
research into their pharmacokinetics and pharmacodynamics
(PD/PK).
Often compared to conventional antibiotics in the lay press,
the capability to kill bacteria is the only similarity that whole
phages and antibiotics share. Therefore, whole phage therapy is
often complicated by additional factors and as such possesses
unique pharmacokinetics and pharmacodynamics that remain
poorly understood. Amongst these unique characteristics is
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the poor diffusion of phages as the result of their immense
size when compared to antibiotics (∼106 times larger). This
means that whole phages cannot be administered in high
concentrations (>1010 PFU). In order to provide an equivalent
amount of “drug” compared to a 10 day course of penicillin
(assuming equal minimum inhibitory concentrations and non-
replicating phages) over 100 Kg of phages would be required
(Bancroft and Freifelder, 1970; Nilsson, 2014). This lack of
diffusion and restricted dosage concentration can be offset by
the ability of phages to replicate upon finding their target
organism.
As with all antimicrobial agents, the ever present shadow
of resistance is particularly relevant to whole phage therapies
where bacterial exposure to phages provides a co-selective
pressure to develop and evade resistance. In the case of
conventional antibiotics, targets are often essential metabolic
functions, while phages and phage derived products (e.g.,
endolysins) primarily target surface structures, among the most
rapidly changing features in bacteria. The epoch spanning
co-evolutionary arms race between phages and bacteria have
also resulted in the development of a number of distinct and
constantly evolving anti-phage systems, most famously CRISPR-
Cas systems (Horvath and Barrangou, 2010), to protect bacteria
from infection by phages. In addition to CRISPR-Cas systems,
other bacterial resistance mechanisms exist including phage
exclusion and restriction modification systems, and have been
discussed extensively elsewhere (Hyman and Abedon, 2010).
While such systems present a threat to the overall efficacy of
a whole phage therapeutic, they are not universally distributed
in bacterial species (Grissa et al., 2007; Burstein et al., 2016)
and phages also develop counter measures to these resistance
mechanisms (Maxwell, 2016).
Although humans are routinely exposed to phages on a
daily basis, concern persists over their immunogenicity and
overall safety, presenting an additional stumbling block for the
adoption of phage therapy. High doses of phage proteins can
elicit unwanted side effects from stimulation of the immune
system (Gorski et al., 2012; Dabrowska et al., 2014). Due to their
classification as biological therapeutics (Rose et al., 2014), both
whole phage therapies and therapies based on phage derived
products will need to be manufactured under current good
manufacturing practices (cGMP) and also adhere to current
pharmacopeia requirements that are based on the type of
application. This will require not only large scale manufacturing
in inert suspension media, something being addressed by
small biopharma, but also production of ultrapure preparations
conforming to strict endotoxin requirements (<0.5 EU/mL for
subcutaneous injections).
CURRENT CLINICAL TRIALS REGULATION
The regulatory foundation for clinical studies and clinical
trials in humans is to ethically establish the potential toxicity,
efficacy and side effects of new drugs and to prioritize the
health of the participants over the generation of results. It
is equally important that sufficient data support the claim of
potential benefits and that these benefits outweigh anticipated
risks. Clinical studies and trials should be carried out in
a scientifically correct and transparent manner, be designed
to result in trustworthy data and assess the pharmacological
properties of the new drug in a stepwise process adapted to
available information.
PRE-CLINICAL TESTING
In the current paper, a number of points will be discussed
that specifically impact upon individual licensing pathways. In
addition, there are a number of pre-clinical testing issues which
need to be addressed prior to use in patients regardless of the
approval process. These include the need to develop standard
testing protocols such as those found in antibiotic (e.g., BSAC
or EUCAST; Brown et al., 2016) or microbicide biocide testing
(e.g., ASTM E2197) to ensure consistency in results. There is
an ongoing shift from classical qualitative assays such as the
spot test (host range is assessed by plaque formation) to more
quantitative methods such as the efficacy of plating (number of
plaques on a target strain compared to number of plaques on
the routine host; Khan Mirzaei and Nilsson, 2015), protocols
still vary between laboratories. The creation of international
standards would ensure the reliability and reproducibility of data.
Standard “efficacy” criteria are utilized by companies seeking
to claim activity for chemical microbicides against a particular
pathogen (e.g., a defined strain of S. aureus as an analog for
MRSA). These activities are often under defined environmental
and test conditions utilizing a reference strain as the target (e.g.,
ASTM E2197)1. Currently no such standardized criteria exist for
whole phages. Although whole phages are unlikely to achieve
such large reductions in short time periods (usually ≥5log10
reduction in <5 min), suitable criteria could be established.
These criteria could be based upon a defined lower kill level,
the persistence of antibacterial activity over prolonged periods
of time, or other virulence characteristics (Borysowski et al.,
2014). Such criteria would enable multiple libraries based on lytic
activity to be assembled for custom made therapies.
CLASSICAL CLINICAL TRIALS
Clinical trials in the United States must be carried out in
accordance with laws in the United States Code, title 21, chapter
9; the Federal Food, Drug and Cosmetic Act and in particular
part A of subchapter V: Drugs and Devices (http://www.fda.gov/
RegulatoryInformation/Legislation/FederalFoodDrugandCosme
ticActFDCAct/FDCActChapterVDrugsandDevices/default.htm
#Part_A; accessed 13th June 2016) under the jurisdiction of
the FDA and have influenced the regulations of many other
countries due to their comprehensive nature. Within the EU,
clinical trials are currently performed in accordance to the
Clinical Trials Directive (EU-CTD). This should be superseded
in 2016 by the simplified and updated Clinical Trials Regulation
1ASTM E2197-11, Standard Quantitative Disk Carrier Test Method for
Determining the Bactericidal, Virucidal, Fungicidal, Mycobactericidal and
Sporicidal Activities of Liquid Chemical Germicides, ASTM International, West
Conshohocken, PA, (2011), www.astm.org.
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(EU-CTR; http://ec.europa.eu/health/human-use/clinical-trials/
directive/index_en.htm; accessed 13th June 2016), allowing a
single application in one member state to apply to all EUmember
states which would participate in the trial.
Clinical trials are often broken into four distinct phases
(Figure 2) following successful pre-clinical studies. These phases
increase in complexity and size as a product moves closer to
approval. Should approval be granted, all products are then
subjected to rigorous routine review as they are used. These stages
have been reviewed in detail elsewhere (Pocock, 1983) and are
summarized in Table 2.
It is estimated that ∼US$2.6 billion is required to successfully
go from concept to an approved drug (Mullard, 2014).
Although some of the initial screening has been taken up
by academia (mainly pre-clinical and development work), a
significant investment of time and resources is still required from
pharmaceutical companies. When compared to drugs developed
to treat chronic conditions (e.g., statins), the development
of antibacterial agents is economically unviable, due to their
comparatively short usage time.
In response to the pressing need to develop new, safe and
effective antibacterial agents, additional legislation has been
introduced which attempts to modify the approval process,
including limited population approval and the incentivization of
antibacterial drug development (Brown, 2013; Bax and Green,
2015).
THE APPLICATION OF WHOLE PHAGE
AND PHAGE DERIVED PRODUCTS TO
“CLASSICAL” CLINICAL TRIAL
SCENARIOS
Both whole phages and their derived products will be
subjected to the same rigorous clinical trials process
as antibiotics. They are also classified as “Therapeutic
biological products” and thus subject to the Food, Drug,
and Cosmetic Act (http://www.fda.gov/RegulatoryInformation/
Legislation/FederalFoodDrugandCosmeticActFDCAct/FDCAct
ChapterVDrugsandDevices/default.htm#Part_A; accessed 13th
June 2016) and also the Public Health Service Act
(http://www.fda.gov/RegulatoryInformation/Legislation/ucm148
717.htm; accessed 13th June 2016) and under EU Directive
2001/83/EC (Rose et al., 2014; Pelfrene et al., 2016) and would
require additional controls over the manufacturing process.
Should any changes be made to the manufacturing process,
extensive comparability testing would be required to confirm
the consistency of the product (Chirino and Mire-Sluis, 2004).
Regulators, such as the EMA, are aware of the additional issues
faced by phage therapeutics and believe that dialogue with
developers will contribute toward a solution (Kingwell, 2015).
For ease of reference, a number of assumptions have been
made in the current article as follows:
• A single strictly virulent phage or phage derived product
(e.g., endolysin) is selected from pre-clinical studies which
produces a suitable level of bacterial reduction for the intended
application.
TABLE 2 | Summary of clinical trials testing requirements.
Phase Aim Cohort size Notes
Phase I Determination
of safety
20–100 • 1st in human studies using
healthy volunteers
• Evaluation of dosing while
monitored
• Determination of adverse
effects
Phase II Determination
of efficacy
100–500 • Determination of efficacy
in target population
• Evaluation of side effects
Phase III Confirmation
of efficacy
1000–5000 • Verification of efficacy in
target population
• Evaluate rarer side effects
• Comparison to gold
standard treatment
Phase IV Safety
surveillance
–a • Monitoring of routine use
to ensure no adverse side
effects
Adapted from (Pocock, 1983). aNot applicable.
FIGURE 2 | Schematic representation of current FDA approval procedures for anti-infective drugs.
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• The phage or phage derived product has been subjected
to appropriate pre-clinical in vivo testing to determine the
toxicity, immunogenicity, and dosing of the treatment.
• All products should be produced according to cGMP, as
determined by local regulators, as well as being soluble in, and
compatible with, commonly used physiological solutions (e.g.,
saline) or other physiologically inactive media.
• All components of a phage or phage product cocktail must
have been shown to be acceptable as stated above for single
phages. In addition, the dynamics between the individual
components of the cocktail should also be assessed prior to use.
Initial clinical testing (Phase I) will not vary greatly between
antibiotics, whole phages or their derived products and as such
should be relatively simple to perform with the appropriate
approvals. The routine exposure of humans to phages provides
the immune system with a low level of circulating phage-specific
antibodies (Kucharewica-Krukowska and Slopek, 1987) and
subsequent exposure as part of a therapy may compound this.
Indeed a number of in vitro and in vivo studies have shown that
phages stimulate the innate and adaptive immune systems in a
phage specific manner (Dabrowska et al., 2014; Majewska et al.,
2015) and potentially in a protein specific manner (Dabrowska
et al., 2014). However, a number of studies performed with
cocktails of whole phages have suggested that phages are harmless
when ingested (Table 3; Bruttin and Brussow, 2005; Sarker et al.,
2012) or applied topically (Rhoads et al., 2009). This lack of
response may be in part due to the degradation of phages as they
transit the digestive system, reducing the number that come into
contact with immunostimulatory cells (Abedon, 2015), but also
due to varying degrees of sensitivity between different cell types.
Despite this initial suggestion of safety under Phase
I conditions, potential safety issues will remain during
Phases II–IV as “rarer” side effects are sought. At these
stages, drugs under evaluation are subjected to trials of efficacy
in a population who suffer from the particular disease under
investigation. Due to the nature of the lytic phage lifecycle, it
is not inconceivable that the active replication of phages at a
site of infection could produce side effects, such as toxic shock,
as bacterial debris is released. Such issues could potentially be
anticipated and avoided by the selection of phages which exhibit
different properties such as lower virulence or through the
combination of phages with conventional antibiotics. Although
this may suggest that whole replicating phage therapies could
be consigned to topical application further research is required,
particularly if the issue is addressed through the incorporation
of anti-endotoxin adjuvants (de Tejada et al., 2015; Valera et al.,
2015).
During Phase II and III studies additional complications
arise when trying to recruit a statistically relevant homogenous
population to study (Rose et al., 2014). In the case of diseases
caused by a single bacterial species (e.g., cholera), this may be
due to a low incidence in the general population or, and more
likely, the disease can be caused by multiple organisms (e.g.,
diabetic foot ulcers). It is therefore likely that clinical trials on
phages will be based on long term or multi-site studies in order
to obtain representative population sizes and could be facilitated
by the introduction of the EU-CTR. The introduction of the EU-
CTR could also enable trials to be coordinated from specialist
phage therapy centers allowing for the distribution of specialist
knowledge and products.
Although the combination of multiple phages into a cocktail
compensates for a limited host range (Bruttin and Brussow, 2005)
a number of compromises are made. The increased complexity
of multi-phage cocktails will dilute the concentration of the
individual phage components due to their size, and also introduce
competition of phages for binding sites, both of which could
compromise the treatment (Nilsson, 2014).
Pre-made phage cocktails can be designed to target either
against uncharacterized (multiple phages targeting multiple
bacterial species), or typed bacterial infections (multiple phages
targeting a single bacterial species). Additionally, patient specific
cocktails can be produced in which phages are selected from a
pre-existing library against the patient’s specific strain (Pirnay
et al., 2011). While the manufacture of pre-made cocktails would
be tightly controlled and mass produced under cGMP in order to
satisfy regulatory requirements (Parracho et al., 2012; Rose et al.,
2014) it could decrease the production cost per dose. Pre-made
cocktails would also require supplementary approval as cocktail
components are modified to compensate for the development of
bacterial resistance. The clinical usefulness of pre-made cocktails
would be limited due to the shifting nature of epidemic strains;
however, the rate at which resistance develops under therapeutic
conditions is currently unknown. In theory at least, a pre-defined
cocktail should be able to successfully navigate the current
regulatory process assuming appropriate non-inferiority (drugs
under investigation possess similar levels of activity compared to
standard treatment) trial designs. However, it remains unclear
if additional approval would be required as components of the
cocktail change.
Although patient specific cocktails may provide better overall
results (due to the tailored nature of the treatment) these
would present additional challenges in order to gain regulatory
approval. Classical trials of patient specific cocktails would have
to be designed to target specified bacterial strains within the same
species, further reducing the available population which could
be recruited and require multi centered trials to be undertaken.
In theory at least individual approvals would be required due to
their unique composition. In order to compensate for the variety
of potentially infectious strains, patient specific cocktails would
require libraries of pre-approved phages to be developed. This
would allow cocktails to be assembled on a case by case basis,
currently an unprecedented move, although the stockpiling of
vaccines and some antitoxins could be considered to be a suitable
analog (Bodas et al., 2012; Martin et al., 2012).
As previously mentioned, the overall cost for the complete
(pre-clinical to Phase III) development of a novel drug is
astronomical (estimated to be US$2.6 billion; Mullard, 2014)
and represents a significant obstacle for the broad evaluation
of phage therapy in human populations. This cost would be on
a per cocktail basis (assuming cocktails were pre-defined and
manufactured) and probably equate to those encountered by an
antibiotic or phage derived protein. When new strains arise, for
which the pre-defined cocktail is not approved, treatment could
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TABLE 3 | Current clinical trials for phage based therapy in humans.
Trial number Study title Status (date of
completion)
Summary of trial Published research articles
NCT02664740 Standard treatment
associated with phage
therapy vs. placebo for
diabetic foot ulcers infected
by S. aureus (PhagoPied)
Not yet recruiting • Multicenter trial comparing phage impregnated
dressing (107 PFU/mL) to a placebo dressing
• Dressings to be replaced at Day 7 and 14
• Wants to recruit 60 participants
• Measuring wound healing over 12 weeks
• Presence/absence of bacteria and antibiotic resistance
–a
NCT02116010 Evaluation of phage therapy
for the treatment of
Escherichia Coli and
Pseudomonas aeruginosa
wound infections in burned
patients (PHAGOBURN)
Recruiting (July
2016)
• Phase I/II multicenter trial comparing phage cocktails
against Silver Sulfadiazine
• Time taken to get a persistent reduction of bacteria
relative to bacterial content at D0
• Assessing tolerance to the treatment
• Assessing level of clinical improvement
–a
NCT01818206 Bacteriophage effects on
Pseudomonas aeruginosa
(MUCOPHAGES)
Completed (April
2012)
• Induced sputum samples taken from 59 CF patients
• Ps. aeruginosa count after 6 and 24 h exposure to
phage cocktail
• Phage counts after 6 h
Saussereau et al., 2014
NCT00945087 Experimental phage therapy
of bacterial infections
Unknown (Last
Updated Sept
2013)
–a
NCT00663091 A prospective, randomized,
double-blind controlled
study of WPP-201 for the
safety and efficacy of
treatment of venous leg
ulcers
Completed (May
2008)
• Phase I safety study evaluating an 8 phage cocktail
(each phage component approx. 109 PFU/mL)
• Desired enrollment of 64
Rhoads et al., 2009
NCT00937274 Antibacterial treatment
against diarrhea in oral
rehydration solution
Terminated (Jan
2013)
• Comparison of 2 separate T4 phage cocktails against
standard oral rehydration solutions in ETEC and EPEC
infections
• Desired enrolment of 120
• Assessment includes safety tolerance and reduction of
stool volume and frequency
Sarker et al., 2016
Data obtained from http://www.Clinicaltrials.gov (09/03/16). aNot applicable.
still be carried out under compassionate usage or “off license.”
However, in the case of patient specific cocktails, approvals
may have to be obtained on a phage by phage basis, prior to
combination into cocktails and could potentially, increase overall
costs by orders of magnitude.
The biology and unique, but poorly understood, PD/PK of
whole phage based therapies, may in actuality reduce their
viability as antibiotic replacements for the treatment of bacterial
infections in humans. In the case of PD, their large size and
poor diffusion through non-aqueous mediums would present
challenges if used as a systemic treatment. This would require
potentially huge doses of phage to be administered in order
to achieve a therapeutic effect. In terms of pharmacokinetics,
large phage doses would be cleared efficiently from the body by
the immune system and could prevent the establishment of a
productive phage infection. The administration of large doses of
phages would increase the probability of phages being able to
reach the site of infection prior to being removed by the immune
system. In addition to this, the overall immunostimulatory
capacity of phage could be reduced through complex formulation
by masking the phages (Kim et al., 2008) or through modification
of phages to alter immunostimulatory proteins (Dabrowska et al.,
2014).
Although many of the issues raised here have been presented
as phase specific, they in fact transcend the individual trial phases
and represent incompatibilities within the current approvals
process itself. Indeed, for patient specific cocktails, it is highly
improbable that current regulations would allow for the approval
of a library rather than requiring the approval of each individual
phage, drastically increasing the overall cost.
Conversely, phage derived products (e.g., endolysins) may
address some of these limitations and have attracted some
attention from commercial entities (Table 2). Despite being
defined as “therapeutic biological products” their activity
kinetics, and probably approval pathways, would be more akin
to antibiotics than whole phage cocktails. The ability to produce
them as recombinant proteins in a non-target vector means
that overall manufacturing and purification processes could
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be adapted from currently existing methods (such as those
used to produce insulin). This would allow for classification
at a substantially higher level of detail than is possible with
whole phage cocktails. The activity of endolysins has also been
shown to transcend single bacterial strains in Gram positive
pathogens such as S. aureus (Fischetti, 2016). This would not
only enable trials to be performed on larger populations but
could also increase their attractiveness to larger scale pharma
companies, as they could be used to target multiple conditions
caused by a particular bacterial species. However, they would be
of limited effectiveness against polymicrobial infections. Many
of the derived endolysins currently described in the literature
target Gram positive pathogens (Fischetti, 2010; Nakonieczna
et al., 2015). Further research is needed to evaluate their efficacy
against Gram negative pathogens due to differences in cell wall
composition as well as more research on Gram negative specific
endolysins (Dong et al., 2015; Oliveira et al., 2016). Additionally,
other phage derived proteins such as holins and tailspikes may
provide suitable alternatives to endolysins for Gram negative
pathogens (Saier and Reddy, 2015).
ADAPTIVE LICENSING FRAMEWORKS
The process for gaining regulatory approval for novel antibiotics
is a long and time consuming process, which is further
complicated when whole phages are applied to these proceedings.
Although the process itself is optimized for certain types of drugs,
regulators believe that the current trials legislation is “adequate”
for use with bacteriophage based therapies (Verbeken et al., 2012;
Pelfrene et al., 2016). However, many researchers engaged in
the field actively disagree with this, as the current approvals
procedures are too rigid and too costly in terms of time and
money. They havemore recently suggested that current pathways
need to be modified or novel pathways need to be developed for
use with phages (Verbeken et al., 2014; Kutter et al., 2015; Young
and Gill, 2015).
Multiple initiatives have been taken by both the FDA and
Europe Medicines Agency (EMA) to simplify and shorten the
approvals process for drugs while maintaining standards. They
are not designed for antibacterial drugs or, more specifically,
phage based therapeutics. These frameworks include an EMA
pilot project on adaptive licensing initiated in 2014 (AL or
adaptive pathways) and encompasses six undisclosed products.
The pilot study, which is due to report later in 2016, seeks to
investigate how current regulations can be optimized for the
approval of new drugs in cases where there is a highmedical need.
The pilot also seeks to determine which criteria should apply for
drugs that can be approved in a graduated simplified process.
Introduced to the US Senate in January 2015, the Promise
for Antibiotics and Therapeutics for Health (PATH) Act (S.185;
https://www.congress.gov/bill/114th-congress/senate-bill/185/
text; accessed 13th June 2016) is an amendment to section 506
of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 356).
This amendment proposes the creation of a “limited population
pathway for antibacterial drugs” that will allow for the approval
of antibacterial drugs within a highly defined population
without the need for clinical trials through the development
of a Benefit-Risk profile that reflects the “severity, rarity, or
prevalence” of the infection. Although the decision making
process could inevitably be informed by both traditional (e.g.,
survival), alternative (e.g., bacterial clearance), and small clinical
data sets, the process may also take into consideration other
supplementary information such as non-clinical susceptibility
and pharmacokinetic data. However, the supplementary set of
considerations will be decided on a drug by drug basis. Once
approved, product labeling will reflect the limited population
that the drug can be used on and subjected to post approval
monitoring. Subsequent approval for use within a wider
population can be sought, but it is not clear if this would require
full clinical trials or if off license use would be permitted.
AL pathways are iterative processes in which treatment
outcomes are used to inform the ongoing trial, through
the involvement of all stakeholders, as well as input from
independent scientific advice. The iterative process can, as
in the EMA pilot project, be based on different conditions
including: (i) the introduction of more steps, starting with a small
highly defined patient population which is expanded as more
information becomes available (ii) conditional approval for a
product that is granted based on existing data, or (iii) adopting
a centralized compassionate use of a new drug.
ADAPTIVE LICENSING FOR PHAGES
When compared to classical trials, AL pathways may provide
additional flexibility that would enable whole phage therapeutics
and their derived products to be approved for clinical use.
These opportunities would come in the form of initial limited
population testing and potentially through the use of non-
traditional surrogate endpoints.
Regardless of the pathway employed, phage clinical trials will
inevitably consist of a series of compromises due to the complex
interplay between infection type, causative agent and therapeutic
strategy. Trial outcomes will also shift depending on additional
priorities such as clinical need, scope of the trial, anticipated
efficacy of treatment, and overall cost. In addition to this, trials
could be based around amultitude of different formulations, each
possessing advantages and disadvantages (Figure 3).
FORM OF THERAPY
As previously mentioned, phage therapy may involve treatment
with single phages, phage derived products e.g., endolysins, or
cocktails. Host range considerations would limit the available
population that could be treated with single phage preparations,
whereas the formation of phage cocktails would be able
to increase the number of patients that could be treated.
The number of potential recruits for trials could also be
increased for disease states which cause seasonal outbreaks of
a single clonal type in a confined area (e.g., hospital acquired
Clostridium difficilie infections; Furuya-Kanamori et al., 2015).
Trial participants could be easily recruited for clinical trials of a
single phage, particularly if the target organism is a commonly
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FIGURE 3 | Proposed submission of whole phage based products under an adaptive licensing framework. aCharacterization to be based on genotypic
analysis and lytic activity. b Improvement to be characterized on the basis of classical and surrogate endpoints.
occurring pathogen (e.g., MRSA). The recruitment process
would be also be facilitated by a centralized approvals process
(e.g., EU-CTR) which would enable multi-centered trials to be
performed with a single application. However, many infecting
bacterial strains are temporally or spatially restricted, limiting the
availability of participants.
Phage cocktails, on the other hand, can increase the number of
strains susceptible to infection by one or more of the components
which make it possible to target common bacterial infections
caused by different strains in different patients and thus facilitate
the recruitment of participants. Cocktails can be pre-made and
targeted against common pathogenic strains or custom made,
either upon the emergence of a particular strain or to fit the
requirements of individual patients (Pirnay et al., 2011).
Pre-made Cocktails
Highly defined pre-made cocktails should be able to fit into
existing AL frameworks as it would be relatively simple to
define a limited population, although this would not be able
to compensate for differences between causative strains. Should
the causative strain be specified (e.g., Pseudomonas aeruginosa
PAO1) this would further limit the population which could be
recruited, therefore a multi-centered approach would be needed
and could be expedited by the modified EU-CTR. To compensate
for shifting global trends, clinically relevant bacterial collections
should be assembled and distributed which would enable easier
isolation of suitable phages. It should also be noted that pre-
defined cocktails are less flexible to the rise and fall of new
bacterial strains and would ultimately be susceptible to the
development of bacterial resistance. The overall efficacy would
decrease over time in which a new cocktail would need to be
developed and approved for use.
Custom Cocktails
Custom made cocktails are one way to address the development
of bacterial resistance against phages. In the case of bacteria
which harbor phage resistance systems (e.g., CRISPR), phages
encoding specific anti-defense mechanisms e.g., anti-CRISPR
systems (Bondy-Denomy et al., 2013) could be given higher
priority even if their infection characteristics are not as good as
other phages. Several phages targeting different surface receptors
could be applied simultaneously or serially, resulting in a
synergistic effect and could reduce the potential for resistance
developing (Schmerer et al., 2014) although other criteria could
be used for the selection of cocktail components (Chan and
Abedon, 2012). The inducement of synergy between phages
would also be a good strategy for long term treatment of
deep infections. In such infections, phages would have difficulty
reaching their targets and would be cleared by the immune
system reducing their overall number. By inducing synergy a
smaller overall number of phages would be required to reach
the site of infection as each phage component would be able to
establish a productive infection. However, as with all phage trials
there are arguments that the overall number of participants in
custom cocktail trials would be limited to just one (Eichler et al.,
2015) as infecting strains, and therefore cocktail composition,
would vary on a patient to patient basis. As such it may be
advantageous to inform AL trials based on a pre-characterized
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library of phages against a defined pathogen in a defined
condition (e.g., Ps. aeruginosa burn infections), although this
would require a significant redesign of approvals processes.
Creation of a Pre-characterized Library of
Phages and Selection for Use in Patients
A long-term possibility for the implementation of whole phage
therapeutics would be to create phage libraries containing the
most efficient phages against the most severe pathogens, e.g.,
multiresistant Gram-negative bacteria. This could be done by
initially pooling existing phage banks (most of them maintained
by research institutions) into common libraries, followed by
the continuous isolation and addition of new phages. Copies
of the library would be stored in national phage depositories
or major hospitals. This would shorten the time for finding
highly efficient matching phages and assembling cocktails as
well as facilitate an approval process. Individual phages would
initially be characterized in vitro (as with most isolation and
characterization papers) using structural, genomic (i.e., absence
of lysogenic properties), host range, and efficacy analyses (Malki
et al., 2015; Sauder et al., 2016). However, and more importantly,
the pre-characterization could also establish safety and efficacy
including suitable in vivo testing in animal models before phages
are added to the library. It is important to ensure that even phages
which do not meet the required in vitro efficacy criteria (e.g.,
insufficient lytic activity) are not discarded as they may perform
better in vivo (e.g., less immunostimulatory), or possess greater
efficacy against future epidemic strains.
The assembly of pre-approved phage libraries could
potentially prove advantageous as it would allow for the
creation of multiple cocktails to target an individual infection
type within a single library thereby increasing the population
size that could be recruited. Only the cocktails themselves would
need to be tested for safety and efficacy since individual phages
in the library would already be fully tested. This approach would
also allow for the creation of additional libraries for phages
which appear to be less active or possess a restricted host range.
Indeed the possibility of creating multiple or tiered libraries (as is
the case with multiple lines of antibiotics) would allow additional
flexibility as resistance to individual phages develops. However,
as the complexity of cocktails increases to treat polymicrobial
infections, or as multiple tiered libraries are assembled, the
overall cost and time required to complete trials would increase.
It should be noted that the concept of pre-approved libraries
would require a radical shift in the thought processes of
regulatory agencies and would require the development of new
assessment criteria. These criteria could include the absence
of non-toxicity regardless of the combination of phages used,
in combination with a “minimal” activity level of each phage.
Such a shift in thought process would also ultimately lead to
the development and approval of libraries of phage derived
antibacterial proteins. By approving both phages and their
derived proteins as libraries rather than on an individual basis,
the overall number of trials would be reduced due to increased
flexibility of the drug and potentially an increased treatment
success rate.
Patient Criteria and Emergency
Procedures
Following the successful formation of a pre-characterized library
or specified cocktail, patients would be recruited on the basis
of confirmed infection type (i.e., a specified bacterial agent in
a specified disease state). As in the EMA pilot studies, the
trial would progress iteratively, starting with small groups of
participants and resolving uncertainties before expanding the
trial into new populations. Adverse effects influenced by rare
human genetic traits may be problematic for this type of AL
approach, but further research is required. As a consequence,
the initial (human) testing of phages or cocktails from the
libraries should be conducted in non-life threatening topical
infections (e.g., diabetic foot infections). Any target infection
should also have at least one additional treatment available as a
safety precaution. Should the application of the cocktail result
in Serious Adverse Events/Serious Adverse reactions, Suspected
Unexpected Serious Adverse Reactions or no measurable clinical
benefit, the decision to remove a patient from the treatment
should be made quickly and alternative treatment applied as soon
as possible.
Assessing Outcomes and Expansion of
Populations
The necessary expansion from small groups of trial participants
to larger cohorts during adaptive pathway trials would be
contingent on the outcomes that can be assessed given the actual
cohort size. Classical clinical trials often use well-defined and
clinically relevant endpoints like patient survival time, resolution
of infection, decrease in lesion size or perceived symptoms, but
surrogate endpoints based on biomarkers for indirect assessment
can also be applied (Fleming and Powers, 2012).
In the initial stages, classical endpoints should be included
in adaptive pathway phage therapy trials, but pharmacological
assessment will be as important. Surrogate endpoints will
probably be of greater importance for phage therapy trials.
Increase in phage titers, reduction of bacteria load or
infection parameters (e.g., CRP) and absence of additional
pro-inflammatory responses may indicate that the treatment has
a positive effect and that the study can be widened. Therefore,
phage trials under AL would be designed as non-inferiority
trials, in which the intervention is compared to the conventional
therapy (e.g., antibiotics) to establish a similar level of overall
effect (D’Agostino et al., 2003) rather than having to demonstrate
superiority.
If applied in a pre-formed library format for patient specific
cocktails, individual phage components could potentially be
scored to further inform and develop the library. Such a scoring
mechanism would not only require the treatment outcome to be
established, but the actual role of the individual phage in that
outcome and would require the ability to differentiate between
the components of the cocktail.
AL pathways offer many possibilities for the approval of
whole phages. However, each of these different avenues require
compromises which will subsequently impact the efficacy of the
treatment and on the overall cost and time required to complete
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trials (Table 4). In the case of cocktails the time and cost to
reach the clinic will increase significantly if it is necessary to
approve each individual component of the cocktail separately.
However, if radical action is taken and libraries of phages against
specified pathogens are approved, this could potentially counter
the increased cost and time.
Although it is likely that phage derived proteins will not suffer
adversely when trying to gain regulatory approval, AL pathways
could still prove beneficial. The use of a limited population
approach would enable data to be obtained while informing
future clinical studies of different disease states, particularly if
developers are interested in systemic application. In addition to
this, classical and surrogate endpoints could be utilized that could
be derived from antibiotic trials (Cornely et al., 2012; Verduri
et al., 2015).
“RIGHT TO TRY” LEGISLATION AND
“COMPASSIONATE USE”
The Code of Federal Regulations (CFR) Title 21, Chapter I,
Subchapter D, Part 312, Subpart I (http://www.ecfr.gov/cgi-
bin/text-idx?SID=43f054659224216924a6379ef9602c2b&mc=
true&tpl=/ecfrbrowse/Title21/21tab_02.tpl; accessed 13th June
2016) and European Regulation 726/2004/EC (http://eur-lex.
europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:136:0001:
0033:en:PDF; accessed 13th June 2016) govern the expanded
access of non-approved medications to patients that have been
submitted for approval by regulatory agencies. Although this is
often under compassionate use guidelines where no alternative
treatment exists (Whitfield et al., 2010) there are increasing calls
to amend the laws in the US to make this process easier through
additional legislation such as the H.R 3012 (Right to Try Act;
https://www.congress.gov/bill/114th-congress/house-bill/3012;
accessed 13th June 2016). Introduced to Congress during July
2015, H.R. 3012 would allow Phase I experimental drugs,
biological products, or devices to be used in terminally ill
patients.
Although such regulations would allow for the use of phages
on individual patients in the US under Part 312.310, expansion to
an intermediate patient population size (Part 312.315) would be
possible, but potentially difficult. While there have been a limited
number of cases in which phage cocktails have been approved
for compassionate use this process is not routine (Rhoads et al.,
2009; Khawaldeh et al., 2011). However, should resistance rates
continue to increase, and the number of available drugs decrease
further, phage therapy may be the only remaining therapeutic
option.
In addition to cGMP and other specific requirements,
informed consent from patients is required for compassionate
use. While this should be relatively simple, the lack of
public awareness surrounding phages may be detrimental to
recruitment. This lack of public awareness could be circumvented
by the formation of trials in EU member states possessing
specialized phage centers (such as the Institute of Immunology
and Experimental therapy in Wroclaw Poland) as part of an EU-
CTR application in combination with compassionate usage in
other parts of Europe which has been suggested by researchers
in the field (Kutter et al., 2015).
UTILIZATION OF ADDITIONAL DATA
SOURCES
The clinical use of phages in specialized centers in Eastern
Europe has generated immense amounts of data, little of which
is published in Western scientific literature (Miedzybrodzki
et al., 2012). As some of these centers now lie within the EU,
data generated post membership should conform to Western
standards and could potentially form the basis of a meta-analysis
or systematic review of clinical phage therapy when combined
with more recent trial data that has been generated.
In order to utilize such data that has been generated prior to
EU membership, or for countries whose regulatory frameworks
may differ to EU and FDA standards, criteria would need to
be established in order to assess the overall quality of the
work performed. This could be done on the basis of the
achievement of an appropriate clinical outcome (i.e., duration of
hospitalization or resolution of infection) or an assessment of the
methodology and trial design prior to incorporation into meta
analyses.
CONCLUDING REMARKS
Despite the pressing need to develop new antibacterial agents, the
approval rate of anti-bacterial drugs remains low when compared
to other forms of drug due in part to both economic and
scientific issues. Phage derived products, such as endolysins, are
likely to be suitable for classical clinical trials procedures due to
their similarities with conventional antibiotics. However, in the
case of whole phage therapies, currently available mechanisms
are not suitable, requiring large patient cohorts and extensive
resources. In this article the limitations of current clinical
approval pathways, as well as possible alternative pathways
for the approval of phage therapy, have been discussed and
summarized (Table 5).
While the current article is by no means exhaustive on every
potential pathway that could be employed for the approval
of phage based therapies for human use, it hopefully sparks
discussion and debate on the nature of clinical trials and the need
for more flexible regulations when dealing with phages and their
derived products. For phages that are genetically similar (>95%)
this could include additional accelerated or automatic approval
pathways. This would be particularly useful for those phages
whose major components (e.g., capsids) are identical but whose
host range and efficacy is influenced by small changes in tail fiber
composition (Ando et al., 2015; Goren et al., 2015). However,
genetic engineering of whole phages (Ando et al., 2015), or the
creation of wholly artificial phages from sequence data (Smith
et al., 2003), would require approvals pathways to be revisited
in the future as these technologies approach clinical readiness.
In the case of customizable cocktails taken from pre-licensed
libraries, suitable regulatory criteria need to be developed. This
would in essence separate phage approvals from the normal
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TABLE 5 | Summary of current and possible alternative pathways as applied to whole phage and phage derived therapeutics.
“Classical” licensing Adaptive licensing Compassionate use
Advantages • “Gold” Standard
• Already established for antibacterial drugs
• Would be suitable for phage derived products
• Additional legislation being introduced to
streamline procedures for antibacterial drugs
• Limited population approvals
• Iterative process which can inform
future work
• Can be adapted for pre and custom
phage cocktails
• Immediate clinical usage
• Data could be used to inform future work
• Could be utilized for all forms of phage
therapy
Disadvantages • Recruitment for trials
• Cost
• Reformulation would require additional trials
• Varying degrees of complexity
• Limited population approvals
• Limited to a single patient basis
• Not actually approved for use
Other considerations • Likely that only highly defined products would be
able to succeed, limiting success
• Approval of predefined libraries would
require wholly new approvals process
• Lack of public awareness of phages
Time to implementa ++ ++ or +++* +
Cost to implementa $$$ $$ or $$$* $
aAssumption has been made that “Classical” licensing is a baseline. *Both cost and time to implementation would be affected by the form of treatment chosen. Pre-approved libraries
taking longer and costing more to achieve.
biological therapeutics approvals and would require a substantial
shift in the collective mindset of regulatory agencies.
Perhaps the most radical possibility would be to establish
a centralized phage bank under governmental control from
which phages could be isolated, collated, tested, and distributed
on a case by case basis to be used in compassionate use
treatments or AL trials. Data and treatment outcomes could
then be collated by the phage bank to provide greater insight
into phage therapy as a whole. This would not only remove
the commercial element to development, but would provide
direct to clinic access for therapies and also enable a greater
degree of control to be exerted over treatment potentially
reducing phage resistance rates. Such a system could be
developed within existing public health organizations (e.g.,
Public Health England, UK or Folkhälsomyndigheten, Sweden)
as these organizations are responsible for collating data on
antibiotic resistance trends and provide reference laboratory
facilities, but would require a substantial initial investment to
establish and thus may be unpalatable in the current economic
climate.
While no phage specific approvals pathway currently exists,
such a pathway could be developed with suitable engagement
between regulators and researchers. This pathway could be
based on existing guidelines, where products which have been
successfully completed phase I clinical studies are applied on a
case by case basis under compassionate use guidelines. However,
in order to gain widespread adoption it may be better to base
phage approvals on AL principles, whereby approval is granted
for small specified populations which can then be expanded upon
as post-approval data is gathered.
Regardless of the pathway implemented, the overall cost
of drug development and the poor return on investment of
antibacterial agents will remain one of the defining development
issues. Due to the abundance of phages in the environment,
patents may be circumvented relatively easily as new phages are
isolated and would therefore reduce the potential level of interest
from traditional pharmaceutical companies.
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